Solvonis Therapeutics plc (LON:SVNS)

Solvonis Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	May 31, 2021
Net Income	-1.59	-3.12	-2.71	-1.64	-0.45
Depreciation & Amortization	-	0.18	0.11	0.08	0.11
Asset Writedown & Restructuring Costs	-	0.74	-	-	-
Stock-Based Compensation	0.32	0.37	0.86	-	-
Other Operating Activities	0.17	0.19	0.01	0.01	-0.07
Change in Accounts Receivable	0.03	0.01	0.04	-0.1	-0.03
Change in Inventory	-	0.01	-0.19	-	-
Change in Accounts Payable	-0.06	0.39	-0.5	1.2	0.27
Operating Cash Flow	-1.13	-1.24	-2.36	-0.44	-0.17
Capital Expenditures	-	-0.22	-0.72	-0	-0.02
Divestitures	-0.01	-	-	-	-
Other Investing Activities	-0.32	-0.02	-	-	-
Investing Cash Flow	-0.34	-0.23	-0.72	-0	-0.02
Short-Term Debt Issued	0.2	-	-	-	0.2
Total Debt Issued	0.2	-	-	0.51	0.2
Net Debt Issued (Repaid)	0.2	-	-	0.51	0.2
Issuance of Common Stock	1.92	-	4.48	0.86	-
Other Financing Activities	-0.04	-	-0.34	-	-
Financing Cash Flow	2.08	-	4.14	1.37	0.2
Foreign Exchange Rate Adjustments	-0.01	-0.02	-0.02	0.02	-0
Net Cash Flow	0.6	-1.49	1.04	0.96	0.01
Free Cash Flow	-1.13	-1.45	-3.08	-0.44	-0.18
Free Cash Flow Margin	-	-247.70%	-567.90%	-116.44%	-34.81%
Free Cash Flow Per Share	-0.00	-0.01	-0.03	-0.01	-0.00
Levered Free Cash Flow	-0.82	-0.8	-2.81	-	0.09
Unlevered Free Cash Flow	-0.78	-0.8	-2.81	-	0.09
Change in Net Working Capital	0.15	-0.37	1.37	-	-0.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.